Head-to-head evidence
ecnoglutide vs efsubaglutide alfa
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
ecnoglutide
Marketed by Sciwind Biosciences
NCT05813795 · Phase 3 · completed
This was a randomized, triple-blind, placebo-controlled Phase 3 trial in 664 adults with overweight or obesity. Ecnoglutide 2.4 mg produced a significantly greater reduction in body weight than placebo at week 40, -13.2% vs +0.1%, p<0.0001, meeting the trial primary comparison.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: November 2026 · NCT07553299 (registry estimate)
efsubaglutide alfa
Developed by Shanghai Yinnuo Pharmaceutical Technology
NCT06732960 · Phase 2 · completed
The study was randomized, double-blind, and placebo-controlled, but each dose cohort was small, with approximately 10 participants per cohort and a 8:2 active-to-placebo allocation. Because the registry provides no primary endpoint results, it is not possible to determine whether the weight-loss comparison was met.
Next expected readout: November 2026 · NCT07163650 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ecnoglutide's landscape · efsubaglutide alfa's landscape